Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the Company has applied for 510(k) clearance from the Food and Drug Administration (FDA) to market its J-Plasma™ handpiece with retractable cutting features in both laparoscopic and open configurations. The newly developed devices will offer soft tissue coagulation and/or tissue cutting with and without simultaneously applied J-Plasma™ energy. With its extended knife and no conventional RF or J-Plasma™ energy applied, the devices would be similar to a conventional scalpel, suitable for a tissue biopsy. However, by combining J-Plasma™ energy with the extendable knife, the devices offer an enhanced cutting and coagulation capability. Furthermore, no grounding pad is required as with other electrosurgical products, minimizing the risk to the patient and surgeon. The multi-modal devices will allow Bovie to support soft tissue coagulation and cutting in gynecology, general, urology, neurology, vascular, plastics and cardio-thoracic surgery. Bovie will be displaying J-Plasma™ and its added features while attending the 39 th AAGL Global Congress of Minimally Invasive Gynecology in Las Vegas, NV November 8-12, 2010. Commenting on the new devices, Jeff Rencher vice president of sales and marketing for surgical products stated, “The introduction of this new product line will enhance certain surgical procedures and could ultimately contribute to a new standard of care by combining several modalities and techniques into one convenient device while lowering costs.” For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com. Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.